The president announced a major AI investment project, which Oracle Chairman Larry Ellison said could be used to cure cancer.

mRNA vaccine developer Moderna (MRNA ... if you're going to consider investing in Moderna today. Without a growing base of revenue, it's hard to craft a compelling investment thesis for Moderna ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Clinical-stage Australian biotechnology company Vaxxas will receive $3.2 million from the US Biomedical Advanced Research and ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

Lougheed, said the findings of the report were “shocking” and that the information it presents to the public is “long overdue ...

Testing new antibiotics in India, South Africa, or Brazil, where they are needed most, makes scientific sense. But it’s not ...

With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other S&P 500 stocks ... us or make multinational companies move their manufacturing base here to a ...